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Of the multitude of inflammatory mediators and 
reactions investigated hitherto and claimed as being 
at least contributory to the development of an in-
flammatory process, proteolysis-induced patho-
mechanisms seem to play a major role in the prima-
ry response and ultimate outcome of the organism 
to inflammatory stimuli such as tissue destruction 
due to multiple trauma and major surgery or inva-
sive microbes and endotoxins in sepsis. Indepen-
dent of the etiology of the insult, the inflammation 
response is primarily directed towards inactivating 
and eliminating the deleterious agents and to initi-
ate the process of repair and healing. Yet the activa-
tion of the complex interacting cellular and humor-
al defense mechanisms necessary for this purpose 
carries with it the risk of damaging healthy tissue 
as well, thus perpetuating the inflammatory pro-
cess. In this respect, the lysosomal serine proteinase 
elastase and the cysteine proteinases cathepsin B 
and L of the primary inflammatory cells, polymor-
phonuclear (PMN) granulocytes and monocytes/ 
macrophages, respectively, are supposed to be po-
tent effectors of proteolytic tissue damage if they 
are discharged extracellularly in high amounts dur-
ing activation and disintegration of the phagocytes. 
Moreover, the contact between proenzymes of 
the humoral cascade systems and damaged vascu-
lar endothelium together with activators (e.g., tis-
sue factor, plasminogen activator) liberated from 
those cells results in the formation of system-
specific proteases, whose activity is largely respon-
sible for hemostasis and closure of the wound. Yet 
some of these proteolytic enzymes (plasma 
kallikrein, thrombin, plasmin, complement esteras-
es) also produce additional mediators of inflamma-
tion such as the vasoactive kinins, the hemostatic 
and edema-forming fibrin monomers and fibrin 
peptides, or the anaphylactic complement factors 
(C3a, C4a, and C5a). System-specific proteases 
themselves, together with a series of polypeptides 
formed as a result of their proteolytic activity, act 
as potent chemotaxins and bring about the seques-
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tration and activation of inflammatory cells (par-
ticularly PMN granulocytes) in the wound area. 
In addition to lysosomal proteinases cytokines, 
arachidonic acid metabolites and highly reactive 
oxygen species are also extracellularly liberated 
during cell stimulation. By this means, vital struc-
tural elements (basal membranes, cell receptors, 
fibronectin, elastin, collagens, proteoglycans, etc.) 
as well as humoral factors, including a wide variety 
of plasma proteins in close vicinity to the 
phagocytizing cells, may be impaired unless the 
lysosomal proteolytic enzymes and oxidants are in-
activated by their physiological regulators, the pro-
teinase inhibitors (e.g., a,-proteinase inhibitor, 
a! -antichymotrypsin, a2-macroglobulin, cysteine 
proteinase inhibitors) and antioxidants (superoxide 
dismutase, catalase, glutathione redox system, 
ceruloplasmin). 
However, due to an overstressed phagocytic ac-
tivity of P M N granulocytes and monocytes/macro-
phages during severe inflammation, the main an-
tagonist of PMN elastase, the a {-proteinase inhibi-
tor (a!PI) , is highly susceptible not only to proteo-
lytic cleavage by cysteine proteinases (see below) 
and by metalloproteinases released from PMN 
granulocytes (Knäuper et al. 1990), fibroblasts or 
mononuclear cells (Winyard et al. 1991), but also to 
oxidative denaturation of the reactive inhibitory 
site in the molecule (Travis and Salvesen 1983). This 
enables an unrestricted local digestive activity by 
PMN elastase combined with fatal consequences 
for the hemostasis system. As shown by several au-
thors (reviewed by Jochum 1988; Machovich and 
Owen 1990), PMN elastase can easily degrade and 
inactivate the principal inhibitors (antithrombin 
III, a2-p\&smm inhibitor, plasminogen activator 
inhibitor 1, Cl-inactivator) of proteinases of the 
blood cascade systems (clotting, fibrinolysis, com-
plement), thus allowing the maintenance of life-
threatening consumption of hemostasis factors and 
the additional production of potent stimulators of 
the phagocytes as mentioned above. Moreover, the 
proteolytic inactivation of the blood cascade inhib-
itors may be greatly enhanced by their oxidative de-
naturation in the surroundings of phagocytizing 
cells (Stief and Heimburger 1988). 
Just recently, the proteolytic degradation of the 
main human cysteine proteinase antagonists, 
cystatin C and kininogen, by PMN elastase has also 
been demonstrated (Abrahamson et al. 1991; 
Kleniewski and Donaldson 1988). This may further 
aggravate the destructive potency of monocyte/ 
macrophage-derived cysteine proteinases which are 
extracellularly discharged due to serious incidents 
such as multiple trauma and sepsis. 
The tremendously complex interrelationship of 
cellular and humoral proteolytic pathomechanisms 
eventually contributing to the development of mul-
tiple organ failure (MOF) in the course of severe 
acute inflammation is depicted in a very simplified 
version in Fig. 1. A comprehensive review of litera-
ture on this topic is given by Jochum (1988), 
Jochum and Fritz (1989, 1990), Assfalg-Machleidt 
et al. (1990), Neuhof (1990, 1991), and Neuhof and 
Fritz (1992). 
To obtain fundamental information about the 
extent to which proteinases may participate in the 
initiation and perpetuation of inflammatory pro-
Fig. 1. Schematic depiction 
of humoral and cellular 
proteolytic patho-
mechanisms involved in the 
development of multiple 
organ failure (MOF). 
Destructive proteases 
(elastase, cathepsin B) and 
other cell constituents are 
released after activation of 
the phagocytes by blood 
cascade proteinases (plas-
ma kallikrein, factor Xlla, 
thrombin, etc.) and 
polypeptides (fibrinogen 
and fibronectin split prod-
ucts, complement factors 
C3a and C5a, etc.) 
Plasminogen _ Plasmin 
Fibronectin (FN), Fibrinogen ( F ) 
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cesses, the following indications - as a modifica-
tion of the Koch-Dale criteria - have to be proven 
in experimental and clinical studies: 
1. The inflammatory potency (e.g., destruction of 
vital proteins) of the respective phagocyte pro-
teinases (PMN elastase, cathepsin B) has first to 
be shown in in vitro experiments. 
2. The release of the lysosomal proteinases and the 
activation of proteolytic blood cascade enzymes 
has to be verified in correlation to the severity of 
the inflammation. 
3. The consumption of proteinase inhibitors and 
other plasma factors susceptible to proteolytic 
degradation should coincide with the occurrence 
of proteolytic activity. 
4. Specific split products of functional proteins 
generated by the proteolytic action of lysosomal 
proteinases have to be shown in correlation to 
the extracellular release of these enzymes. 
5. The use of specific exogenous proteinase inhibi-
tors as therapeutic tools should prevent or at 
least reduce to some extent severe signs of in-
flammation. 
In the remainder of this chapter, characteristic 
results relating to these demands, obtained from ex-
perimental and clinical studies (the latter dealing 
primarily with multiple trauma), are given in more 
detail. Using the same specific test systems, our 
findings and those of other authors, which will be 
also briefly mentioned, demonstrate clearly the in-
volvement of proteolytic pathomechanisms in 
acute inflammation such as trauma-induced organ 
failure. Therefore, proteinase inhibition may prove 
to be an indispensable therapeutic approach in the 
future to reduce the incident of organ failure and 
mortality in multiply injured patients. 
PMN Elastase and Cathepsins B and L 
as Potent Effectors of Unspecific Proteolysis 
of Vital Proteins 
PMN Elastase 
With regard to the pathological mechanisms in-
volved in severe inflammation, the neutral protease, 
elastase, from the azurophilic granules of the PMN 
granulocytes, stands out as being significant among 
the lysosomal phagocyte enzymes currently recog-
nized. Elastase is not only numerically predomi-
nant ( 3 - 5 ng/106 PMN cells) but also has prac-
tically no substrate specificity in the neutral pH 
range. The latter was shown by the unspecific de-
gradation of a great variety of humoral and struc-
tural proteins such as clotting, fibrinolysis, and 
complement factors, immunoglobulins, transport 
proteins, and proteinase inhibitors as well as basal 
membrane proteins, cell receptors, fibronectin, 
elastin, collagens, proteoglycans, etc. Up to 1990 
more than 90 papers were published describing the 
in vitro proteolysis of at least 45 proteins by iso-
lated PMN release (reviews of literature given by 
Havemann and Gramse 1984, Jochum 1988, and 
Machovich and Owen 1990), and there is still a 
growing number of new reports on this topic. In 
view of the deleterious consequences due to the in-
activation of the main clotting, fibrinolysis, and 
cysteine proteinase inhibitors, as mentioned in the 
introduction, the recently published abrogation of 
the thrombin inhibiting activity of heparin cofactor 
II (Pratt et al. 1990) and of the clotting factor Va 
and Vi l la inactivating capacity of protein S (Oates 
and Salem 1991) and activated protein C (Eckle et 
al. 1991 a) by PMN elastase is also of great interest. 
Moreover, with respect to trauma-induced primary 
lung dysfunctions, elastase-mediated endothelial 
cell injury (Smedly et al. 1986; Inauen et al. 1990) 
and proteolytic destruction of lung surfactant-asso-
ciated proteins by neutrophil elastase (Pison et al. 
1989) are especially worth mention. Finally, the in-
activation of the neutrophil stimulating tumor ne-
crosis factor and its receptors that can be provoked 
by elastase (Scuderi et al. 1991; van Kessel et al. 
1991; Nortier et al. 1991; Proteu et al. 1991) opens 
interesting new questions concerning the auto-
regulatory mechanisms of an inflammatory pro-
cess. Additional modulations of the inflammatory 
reaction may be also brought about by new activi-
ties of the generated split products of vital proteins. 
Thus, elastase-produced IgG fragments inhibit 
Chemotaxis and oxidative burst (Eckle et al. 
1991b), whereas proteolysed elastin (Senior et al. 
1980) and a{?\ (Banda et al. 1988a) as well as 
elastase-o^PI complexes (Banda et al. 1988b) 
turned out to be potent chemoattractants. In addi-
tion, the inhibition of human neutrophil superox-
ide generation by proteolysed and complexed a r 
antichymotrypsin has been demonstrated just re-
cently (Kilpatrick et al. 1991). 
Cathepsins B and L 
Compared to PMN elastase, the amount of the 
lysosomal cysteine proteinases, cathepsins B and L, 
in phagocytic cells is much lower (Kominami et al. 
1985; Bando et al. 1986). PMN granulocytes con-
tain only minor amounts of cysteine proteinases 
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(cathepsin B around 1 ng/106 cells), whereas 
this class of proteinases predominates in cells of 
the monocyte/macrophage system (cathepsin B 
0.2 |ng/106, cathepsin L 0.03 ng/106 of rat resident 
peritoneal macrophages; no data are available for 
human cells so far). 
Many cytosolic and extracellular proteins have 
been shown to be degraded by cathepsins B and L 
in vitro (Barrett and Kirschke 1981; Barrett et al. 
1988) , including a {-proteinase inhibitor (Johnson 
et al. 1986), immunoglobulin G (Billing et al. 
1991), elastin (Mason et al. 1986), various types of 
collagens (Maciewicz et al. 1990), and basement 
membranes (Baricos et al. 1988). In general, 
cathepsin B seems to be markedly less active on 
natural protein substrates than cathepsin L. Very 
recently this difference has been explained by the 
existence of an "occluding loop" in the cathepsin B 
structure, hindering the access of protein substrates 
to the active site cleft of the enzyme and favoring 
a dipeptidylcarboxypeptidase specificity (Musil et 
al. 1991). 
The elastinolytic cysteine proteinase activity of 
alveolar macrophages (Chapman and Stone 1984) 
seems to be mainly due to cathepsin L (Reilly et al. 
1989) , which is 100-fold more active on elastin than 
cathepsin B (Mason et al. 1986). (^-Proteinase in-
hibitor is effectively cleaved and inactivated by 
catalytical amounts of cathepsin L (Johnson et al. 
1986). On the other hand, cystatin C, an inhibitor 
of cysteine proteinases, is rapidly degraded by 
PMN elastase (as already mentioned above) and 
converted into a fragment with drastically reduced 
inhibitory function (Abrahamson et al. 1991). This 
would explain the strong positive correlation be-
tween cathepsin B and neutrophil elastase activity 
and the negative correlation between elastase activ-
ity and cystatin C content observed in purulent spu-
tum (Buttle et al. 1990). 
Against synthetic substrates, cathepsin B is opti-
mally active around pH 6.0, but many proteins are 
degraded more effectively at a lower pH. On the 
other hand, significant activity of cathepsin B can 
be observed even at pH 7.0-8 .0 , with a half-life of 
about 30 min at pH 7.4 (Machleidt et al. 1986). The 
enzyme seems to be stabilized by the presence of 
large protein substrates (Sloane 1990). Cathepsin L 
is rapidly inactivated at neutral pH but its half-life 
at pH 7.4 is still about 8 min (Machleidt et al. 
1986). An acidic pH milieu favorable for cysteine 
proteinase activity can be expected in the microen-
vironment of adherent macrophages (Silva et al. 
1988). Moreover, a form of cathepsin B has been 
found in sputum that, unlike the enzyme isolated 
from liver or spleen, is unusually stable at neutral 
and mildly alkaline pH (Buttle et al. 1988). Al-
though the molecular basis for these physicochemi-
cal differences has not been fully elucidated, the al-
tered pH stability may be pathobiochemically rele-
vant. For full activity of cysteine proteinases a 
reductive milieu is required which is probably pro-
vided by cysteine within the lysosome (Lloyd 1986). 
We have experimental evidence, however, that a sig-
nificant portion of the cathepsin B activity of 
blood plasma and peritoneal exudate is preserved 
in the absence of thiols. 
Cathepsin B and cathepsin L are completely dif-
ferent in their affinity for their endogenous protein 
inhibitors (cystatins, stefins, kininogens). Cathep-
sin L is quasi-irreversibly bound to most inhibi-
tors (dissociation constants, K j<5pM) whereas 
cathepsin B forms only loose complexes with cysta-
tin C (Ki = 0.8nM) and LMW-kininogen (K{ 
= 390 nM). We have shown that cathepsin B activi-
ty in blood plasma and peritonitis exudate results 
from active enzyme dissociating from its inactive 
inhibitor complexes upon dilution in the assay 
(Assfalg-Machleidt et al. 1988, 1990). Liberation of 
active cathepsin B by dissociation may occur in 
vivo wherever the local concentration of complexes 
is diminished. In contrast, due to its pH instability 
and its tight binding to inhibitors, cathepsin L ac-
tivity should be extremely shortlived when released 
from the lysosome and should not be detectable in 
the circulation or in inflammatory secretions. The 
high proteolytic potential of cathepsin L (see 
above) could become destructive, however, when 
the enzyme is discharged in an acid microenviron-
ment under conditions of a local proteinase-in-
hibitor imbalance. 
PMN Elastase and Macrophage-Derived 
Cathepsin B Release 
in the Posttraumatic Course 
Methods 
Serially drawn citrated plasma and broncho-
alveolar lavage fluid (BALF) samples were used to 
quantify proteinases, inhibitors, and other plasma 
proteins as well as their split products. 
Measurements of the lysosomal serine pro-
teinase PMN elastase were carried out with a com-
mercially available, highly specific two-site sand-
wich enzyme immunoassay kit (E. Merck, Darm-
stadt, Germany), which detects elastase only as an 
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inactive complex with a{Pl (detailed description 
by Neumann and Jochum 1984). The normal range 
of circulating complexed elastase in healthy people 
due to the physiological turnover of PMN cells 
amounts to 6 0 - 1 2 0 n g / m l without proteolytically 
active enzyme being detectable. Since, in contrast to 
plasma, BALF samples may contain active elastase 
in addition to the complex, parts of these speci-
mens were also incubated with a surplus of a!PI in 
vitro and reassayed for an increase in elastase-o^PI 
complex as a measure of enzymatic elastase activity 
in vivo. 
The cysteine proteinase cathepsin B activity (up-
per normal plasma level: 50 mU/1) was quantified 
using a specific fluorometric peptide substrate in 
combination with the cysteine proteinase inhibitor 
E-64 as described by Assfalg-Machleidt et al. 
(1988, 1990). Caseinolytic activity of the local body 
fluids due to active elastase and/or cathepsin B was 
detected using resorufin-labeled casein (Boehr-
inger, Mannheim, Germany) as a substrate. The 
method is outlined in detail by the manufacturer 
(Boehringer). 
The coagulation proteinases plasma kallikrein 
and thrombin were estimated by their cleavage ac-
tivity on the chromogenic peptide substrates S-2302 
(Kabi, Stockholm, Sweden) and Chromozym TH 
(Boehringer, Mannheim, Germany), respectively, 
after the turnover of the proenzymes to the active 
proteinases. 
The inhibitory activities of antithrombin III and 
a } PI were measured with commercially available 
test systems (Coatest Antithrombin, Kabi, Stock-
holm, Sweden; a {-Antitrypsin Farbtest, Boehrin-
ger, Mannheim, Germany) applying chromogenic 
peptide substrates for thrombin (S-2238) and tryp-
sin (BAPA), respectively. The antigen levels of the 
inhibitors were quantified with commercial radial 
immunodiffusion plates (NOR-Partigen plates, 
Behringwerke, Marburg, Germany). Opsonic activ-
ity, antigen levels, and split products of the op-
sonins IgG and complement factor C3 were deter-
mined as outlined by Billing et al. (1988, 1990, 
1991) and Machleidt et al. (1992). 
An elastase-specific split product of the Aa-
chain of fibrinogen, called fibrino-elastase-peptide 
(FEP; equivalent to the Aa 1-21 peptide described 
by Weitz et al. 1986), was quantified with a two-
step competitive immunoassay just recently devel-
oped in our laboratory by Gippner-Steppert (1991). 
Clinical methods, criteria for grading the severi-
ty of the disesaes, and treatment of patients are ex-
tensively described in the original publications cit-
ed in the following sections. 
Plasma Levels of PMN Elastase 
and Cathepsin B as Early Indicators 
of Forthcoming Organ Failure 
In an early preliminary clinical trial involving 27 
polytraumatized patients, we were able to show 
that severe injuries of at least two body regions 
(thorax, abdomen, skeletal system) induced a 
prompt and more or less long-lasting release of 
PMN elastase into the circulation (Dittmer et al. 
1986). Measurements were carried out every 4 h up 
to the 28th h and thereafter every 6 h up to the 52nd 
h after trauma. The maximum increase between 5-
and 30-fold of normal of PMN elastase plasma lev-
els with 8 - 1 2 h after the traumatic event correlated 
well with the clinical injury severity score. However, 
due to logistic limitations of the study, it was not 
possible to estimate a predictive value of the ex-
tracellularly discharged PMN elastase for the devel-
opment and outcome of trauma-induced (multiple) 
organ failure. 
In a second approach involving 24 multiply in-
jured patients, we were able to demonstrate that the 
primary activation of PMN granulocytes immedi-
ately after the polytraumatic event is followed by 
repetitive increases of complexed elastase in plasma 
in those patients who developed ARDS and addi-
tional organ failure (Jochum et al. 1989). This mul-
tiple organ insufficiency in our patients was mainly 
due to septic complications. In agreement with 
findings of Nuytinck et al. (1986) and Redl et al. 
(1987), elevated plasma levels of elastase correlated 
well with the severity of injuries and the occurrence 
of multiple organ failure. Moreover, they discrimi-
nated to a reasonable degree at an early stage in the 
clinical course between later survival or mortality. 
To clarify further the potential role elastase -
and in addition cathepsin B - may play in progres-
sive posttraumatic complications, we just recently 
accomplished a more extended exploration. One 
hundred severely injured patients fulfilling previ-
ously defined entry criteria were enrolled in a pro-
spective study (directed by Drs. Nast-Kolb and 
Waydhas, Department of Surgery, Klinikum In-
nenstadt, University of Munich) on inflammatory 
mediators and multiorgan failure associated with 
polytraumatic events (Nast-Kolb et al. 1992; 
Waydhas et al. 1992). Collection of blood samples 
and recording of clinical data were started within 
30 min after arrival of the patients in the emergency 
department (about 1 h after the accident) and con-
tinued on a 6-h basis up to 48 h. Subsequently, the 
monitoring interval was extended to 24 h for a peri-
od of 14 days. Thereafter the clinical course was re-
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Fig. 2 a, b. Mean values (±SEM) of a PMN elastase (in 
complex with a,-proteinase inhibitor) and b cathepsin B 
in plasma of multiply injured patients assigned to three 
outcome groups: *—*, group I (n = 16): nonsurvivors 
with multiple organ failure; 0 - - - 0 group II (n = 47): sur-
vivors with reversible organ failure; +—+ group III 
(n = 37): survivors without organ failure. */?<0.05, 
**/?<0.01 group I vs. group II; # p<0.05 , ••p<0M 
group I vs. group III; A p<0.05 , A A p<0 .01 group II vs. 
group III 
corded until either transfer to a general ward or 
death of the patient. 
Retrospectively, the patients could be assigned 
to three different groups: 16 out of them died due 
to multiple organ failure 3 - 2 8 days (mean survival 
time: 16 days) after the traumatic incident (group 
I), 47 patients survived the development of organ 
failure (group II), and 37 patients overcame the ac-
cident without evident signs of organ dysfunctions 
(group III). 
The extracellular release of PMN elastase and 
monocyte/macrophage-derived cathepsin B into 
plasma of the patients in the three outcome groups 
is depicted in Fig. 2. PMN elastase was in all groups 
elevated significantly above normal (upper range 
120ng/ml) as early as l - 2 h after trauma and 
showed an additional increase up to the 12th h after 
trauma. The differences between mean plasma lev-
els in patients with (groups I and II) and those 
without organ failure (group III) were highly signif-
icant (/?<0.01) throughout the whole observation 
period. Moreover, patients dying due to organ fail-
ure (group I) and those who survived organ dys-
functions (group II) could be also significantly 
0?<0.05) differentiated according to their mean 
PMN elastase plasma concentrations from the 3rd 
posttraumatic day onwards. Cathepsin B plasma 
levels reached their maximum at least 6 h before 
complexed P M N elastase (Fig. 2). This early ca-
thepsin B activity in circulating blood proved to be 
a sensitive and specific predictor of subsequent de-
veloping organ failure. However, it did not discrimi-
nate between fatal (group I) and reversible (group 
II) dysfunctions at that time. In contrast to PMN 
elastase, cathepsin B activity returned to only 
slightly elevated levels within 3 days in all patients 
(Fig. 2), thus not allowing further differentiation of 
the three outcome groups. From these data the con-
clusion can be drawn that the early release of 
lysosomal phagocyte proteinases after a severe trau-
matic event contributes to the occurrence of forth-
coming organ failure, and that at least the ongoing 
discharge of P M N elastase may be involved in the 
exacerbation of the clinical situation. Interestingly, 
the main clotting inhibitor, antithrombin III (AT 
III) , showed a significantly lower inhibitory activity 
0?<0.01) in plasma of our group I and II patients 
vs. those of group III during the whole observation 
period and between nonsurvivors (group I) vs. sur-
vivors with organ failure (group II) from the 1st 
*- o 
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Fig. 3. Mean values (±SEM) of antithrombin III inhibi-
tory activity in plasma of multiply injured patients as-
signed to three outcome groups. For further details see 
Fig. 2 
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Table 1. Prognostic values of plasma levels of PMN elastase, cathepsin B, and antithrombin III on hospital admis-
sion for prediction of organ failure 
Accuracy Sensitivity Specificity PPV NPV 
W (%) W (Vo) W 
Elastase (>200ng/ml) 69 83 44 73 58 
Cathepsin B (>190mU/ l ) 63 50 89 90 48 
Antithrombin III (<80%) 69 79 52 74 59 
PPV, Positive predictive value; NPV, negative predictive value. The discrimination values (in brackets) were evaluat-
ed in a former study (Nast-Kolb et al. 1991) 
Table 2. Prognostic values of plasma levels of antithrombin III and PMN elastase on hospital admission and on the 
3rd posttraumatic day for prediction of death 
Accuracy Sensitivity Specificity PPV NPV 
(<7o) (%) 
Antithrombin III (<60%) 68 80 66 32 94 
Elastase (>500ng/ml) 86 56 91 56 91 
PPV, Positive predictive value; NPV, negative predictive value. The discrimination values (in brackets) were evaluat-
ed in a former study (Nast-Kolb et al. 1991) 
posttraumatic week onwards (Fig. 3). Similar re-
sults were obtained concerning the rapid turnover 
of the coagulation proenzymes prekallikrein and 
prothombin to kallikrein and thrombin, the latter 
being the essential target proteinase of AT III. 
Thus, plasma levels of AT III, prekallikrein and 
prothrombin clearly below 80% of normal in the 
early posttraumatic phase were strikingly associat-
ed with the later appearance of severe organ dys-
functions, indicating that in addition to the release 
of lysosomal proteinases an overwhelming activa-
tion of the humoral proteolytic cascade systems is 
also conductive to the perpetuation of the posttrau-
matic inflammatory process. In Table 1, prognostic 
calculations (accuracy, sensitivity, specificity, posi-
tive and negative predictive value) are given for 
reliable discrimination levels of PMN elastase, 
cathepsin B, and antithrombin III to indicate forth-
coming organ failure or uneventful recovery al-
ready on the patient's admission. The highly pre-
dictive value of early, low AT III inhibitory activi-
ties for a forthcoming exacerbation of posttrau-
matic organ dysfunctions eventually leading to 
ARDS and multiple organ failure was also empha-
sized by Schramm and Spannagl (1991), reporting 
on 57 prospectively studied trauma patients. Fur-
thermore, in our extended study an entry level of 
AT III activity below 60% of normal was highly 
predictive for a later fatal outcome. The same held 
true for PMN elastase concentrations above 5-fold 
of normal from the 3rd posttraumatic day onwards. 
The corresponding prognostic data are given in Ta-
ble 2. 
Plasma Levels of Phagocyte Proteinases 
and Posttraumatic Septic Complications 
Since blunt trauma as well as infectious complica-
tions and sepsis initiate the release of phagocyte 
proteinases, we compared the plasma level patterns 
of PMN elastase and cathepsin B (besides a variety 
of other inflammatory mediators) in subgroups of 
trauma patients suffering from infection/sepsis and 
those who did not sustain these entities (Waydhas 
et al. 1992). In about 70% of patients with organ 
failure early dysfunctions (usually respiratory in-
sufficiency) became obvious during the first 2 post-
traumatic days. Late organ failure predominantly 
due to liver failure emerged after the 3rd day post 
trauma, whereas multiple organ failure was diag-
nosed in 32% of all group I and II patients between 
days 6 and 8. Infections came up around the 3rd 
day post trauma and remained fairly constant for 
about 1 week. Bacterial sepsis occurred slightly de-
layed. According to the three outcome groups infec-
tion/sepsis was verified for 81%/50% of the pa-
tients in group I, for 74%/36% in group II, and for 
2 4 % / 5 % in group III, respectively. Summarizing 
the clinical data, it turned out that in 97% of pa-
tients with an early onset of organ failure infection 
started at least 2 days later than the organ insuffi-
ciencies. In only half of those patients did infection 
or sepsis lead to subsequent deterioration of the 
clinical situation. In contrast, in 50% of the 18 pa-
tients with a late onset of organ failure, infection 
and sepsis preceded the disturbance of organ func-
tions and seemed to have pathogenic significance. 
Interestingly, out of many other inflammation 
markers (Waydhas et al. 1992) only PMN elastase 
showed an obvious correlation with infection or 
sepsis. Since significantly higher plasma levels were 
measurable even before onset of these entities com-
pared to a similar posttraumatic course without 
such complications (Fig. 4 shows measurements in 
group II patients as an example), the conclusion 
can be drawn that granulocytic proteinase may fa-
cilitate and maintain the occurrence of posttrau-
matic infections and sepsis by interfering with the 
immune system (e.g., by degradation of comple-
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Fig. 4 a, b. Mean values (±SEM) of PMN elastase (in 
complex with a,-proteinase inhibitor) in plasma of trau-
ma patients with reversible organ failure (group II). a Pa-
tients with infection (*—*; n = 35) and without infection 
(O—O; n = 12). */?<0.05 infection vs. no infection, 
b Patients with sepsis (*—*; n = 17) and without sepsis 
(O—O; n = 30). *p<0.05; **<0.01 sepsis vs. no sepsis 
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ment factors and immunoglobulins). This assump-
tion is also confirmed by recently published data 
on progressive organ failure in a prospectively stud-
ied group of well-defined multiply injured patients 
(Nerlich 1991). Although no information is given 
about the time of onset of the septic state, signifi-
cantly higher PMN elastase plasma levels were pre-
sented for 18 septic in comparison to 17 nonseptic 
patients from the 24th h up to the 8th day post 
trauma. 
Phagocyte Proteinases in Bronchoalveolar 
Lavage Fluids as Indicators 
of Lung Tissue Damage 
In another clinical study on multiply injured pa-
tients (a detailed study protocol is given by Sturm 
1991) we were especially interested in local proteol-
ysis-induced mechanisms which might be involved 
in the pathogenesis of the most severe lung dys-
function, the acute respiratory distress syndrome 
(ARDS). Daily-drawn BALF samples (method de-
scribed by Obertacke et al. 1991) allowed us to con-
firm a significantly increased local discharge of the 
phagocyte proteinases elastase and cathepsin B in 
subjects at high risk of developing ARDS (Jochum 
1991). As depicted in Fig. 5 (as an example), both 
proteinases showed a repeated though not congru-
ent release in all patients, which indicates more or 
less permanent activation of the phagocytes 
throughout the 14-day posttraumatic observation 
period. Yet, a distinctly lower stimulation of both 
types of phagocytic cells became obvious in the 
non-ARDS subjects compared to patients with 
overt ARDS. 
Although the a)PI antigen levels in all BALF 
specimens of the traumatized patients were far 
above the normal values of healthy volunteers, 
these amounts were apparently not sufficient in 
most cases to inhibit completely the PMN elastase 
released in the local epithelial milieu of the alveoli, 
despite an up to 40-fold molar surplus of the in-
hibitor over the enzyme. Therefore, the obviously 
deficient inhibitory capacity of a ,PI may have 
been caused by proteolytic (e.g., probably due to 
cathepsin B, L) and oxidative denaturation as well. 
Applying special assay systems, both ways of a {PI 
destruction were demonstrated by Schraufstatter et 
al. (1984) at least in some individual BALF samples 
of patients with manifest ARDS. Though other 
authors could not detect elastase activity against 
high-molecular-weight protein substrates in BALF 
samples of ARDS patients (Well et al. 1985; 
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Fig. 5 a, b. Posttraumatic 
courses of overall re-
leased PMN elastase 
(measured as E-a^ PI 
complex) and macro-
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individual patients, a Pa-
tient 429 without ARDS, 















• Casein Prot.-a1PI 
Fig. 6. Proteolytic activity 
(degradation of resorufin-casein 
with and without addition of 
a pro te inase inhibitor) and free 
PMN elastase in serial broncho-
alveolar lavage fluids (BALF) of 
a severely traumatized patient. 
ARDS and multiple organ 
failure persisted from the 5th to 
the 12th posttraumatic day 
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Wewers et al. 1988), we were recently able to show 
caseinolytic activity in a variety of BALF samples 
(kindly given to us by Dr. Obertacke, Department 
of Surgery, University of Essen) from trauma pa-
tients with severe lung dysfunction (Machleidt et al. 
1993). In vitro incubation of these specimens with 
otj PI abolished this proteolytic activity almost 
completely (Fig. 6) and gave rise to an additional 
increase of the elastase-c^PI complex, indicating 
that the enzymatic activity still present in the alveo-
lar fluid was mostly due to PMN elastase. This 
finding does, however, not exclude the proteolytic 
action of cathepsins in situ, since these enzymes 
have a much shorter half-life than elastase and may 
therefore be less active in the stored body fluids. 
PMN Elastase-Induced Fibrinogen 
Split Product as an Indicator 
of Unspecific Proteolysis in Vivo 
The destructive potency of PMN elastase in vivo we 
were able to document directly for the first time by 
proving augmented generation of FEP - a specific 
elastase-induced split product of fibrinogen (Gipp-
ner-Steppert 1991) - in close correlation to the ris-
ing amount of the extracellulary discharged PMN 
enzyme in BALF samples of patients with aggra-
vating respiratory failure (Fig. 7). Hence, the ag-
gressive components of inflammatory cells, espe-
cially the serine proteinase PMN elastase, may in-
deed contribute to the occurrence of lung dysfunc-
tions in severely traumatized patients. 
Moreover, even in plasma samples of such pa-
tients we were able to measure FEP in correlation 
to the continuous release of elastase and the devel-
opment of fatal organ failure as exemplarily out-
lined in Fig. 8. This obvious puzzling occurrence of 
PMN elastase activity in the circulation despite a 
tremendous inhibitory capacity due to a t P I may 
be at least partly explained by the direct contact be-
tween activated PMN granulocytes and platelets via 
fibrinogen (Ruf et al. 1992), which could exclude 
the high molecular inhibitor from the site of prote-
olysis. The assumption of inhibitor exclusion due 
to the close contact of elastase with its respective 
substrates is also confirmed by results obtained 
from several in vitro models utilizing suben-
dothelial matrices or purified proteins such as 
fibronectin, collagens, proteoglycans, etc. (a review 
of relevant literature on this topic is given by Cham-
ba et al. 1991). 
Conclusion 
Summarizing the data obtained in our clinical stud-
ies and those of other authors on patients suffering 
from multiple trauma (and infection), it could be 
clearly shown that the release of the phagocyte pro-
teinases PMN elastase and cathepsin B beyond nor-
mal values evoked by the physiological turnover of 
the phagocytes as well as the activation of proteo-
lytic clotting enzymes closely correlated to onset 
and severity of the acute posttraumatic inflamma-
tory reaction. 
Elastase lug/ml] F E P [ng/ml] 
Fig. 7. Total amount of PMN 
elastase (measured as complex 
with a,PI) and fibrino-elastase 
peptide (FEP) in serial BALFs 
of a severely traumatized pa-
tient with reversible respiratory 
dysfunction from the 2nd to the 
7th posttraumatic day 
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Fig. 8. Plasma levels of PMN 
elastase (in complex with a,-PI) 
and fibrino-elastase peptide 
(FEP) in a poly traumatized pa-
tient with fatal multiple organ 
failure. Resp. F, respiratory fail-
ure; DIC, disseminated in-
travascular coagulation; Ren. F.y 
renal failure; ARDS, acute re-
spiratory distress syndrome; 
Hep. F, hepatic failure 
A presumable inflammatory effector role proved 
especially true for PMN elastase, because the de-
structive potency of this proteinase in vitro could 
be convincingly demonstrated in vivo as well, at 
least on vital humoral proteins in relation to the 
propagation of organ dysfunctions in traumatized 
patients. In contrast, the role of released lysosomal 
cysteine proteinases, cathepsins B and L, as effec-
tors of inflammation in vivo is not yet clear. Con-
sidering the relatively poor proteolytic potency of 
cathepsin B in vitro, it seems probable that simulta-
neously released cathepsin L, which is not detect-
able as active enzyme in the circulation, is responsi-
ble for destructive proteolysis at local sites of in-
flammation. 
Moreover, the studies corroborated without 
doubt that, in patients who have incurred severe 
trauma and infection, the underlying cellular and 
humoral biochemical events are quite similar re-
gardless of the etiology of the insult. Thus, the clin-
ical outcome seems to be only due to the magnitude 
of the inflammatory response, which of course is 
highest if infection is superimposed on trauma. 
Furthermore, it turned out that an excessive lo-
cal (a{Pl) and systemic (AT III) consumption of 
proteinase inhibitors occurs as a main consequence 
of the release of lysosomal phagocyte proteinases 
and the activation of proteolytic blood cascade en-
zymes during severe inflammatory reactions. Since 
this entity seems to be the most critical cause which 
allows the proteolysis-induced (multiple) organ 
damage, supplementation of the body's inhibitor 
potential by exogenous proteinase inhibitors 
against elastase and thrombin - isolated from hu-
man material or produced by gene technology as 
discussed by Fritz et al. (1992) - should be a high-
ly promising therapeutic approach in traumatized 
patients. 
Aspects of Future Therapeutic Approaches 
in Humans 
Use of Elastase Inhibitors 
in the Isolated Rabbit Lung Model 
Although novel therapeutic approaches ultimately 
require validation in well-controlled clinical trials, 
it is virtually always necessary to obtain prelimi-
nary data in animals before employing new drugs 
(e.g., recombinant or synthetic proteinase inhibi-
tors) in humans. Thus, progress in trauma-induced 
multiorgan failure research continues to depend 
upon studies using clinically relevant animal 
models which fulfil commonly accepted criteria of 
specific organ dysfunctions. 
With respect to the interstitial edema formation 
associated with respiratory failure, the first organ 
dysfunction that becomes obvious after a severe 
traumatic event, the isolated perfused and venti-
lated rabbit lung turned out to be a reliable model 
to study new therapeutic approaches for the im-
provement of lung function (Neuhof 1990; Neuhof 
and Fritz 1992). In this model isolated rabbit lungs 
are perfused with Krebs-Henseleit starch buffer so-
lution in a closed circuit and are ventilated by 
means of a Starling pump. The lungs are suspended 
on an electronic balance, allowing changes in lung 
weight indicating edema formation due to a suit-
Proteinases 57 
able stimulus to be monitored continuously. The 
pressure in the pulmonary artery and the left atri-
um are recorded simultaneously to reveal changes 
in pulmonary vascular resistance. 
To understand the role phagocyte proteinases 
may play in the pathogenesis of pulmonary edema, 
two different pathomechanisms have to be consid-
ered with regard to therapeutic consequences. The 
almost reversible formation of interstitial edema in 
the early posttraumatic stage seems to be caused 
mainly by functional alterations (e.g., changing of 
the microvascular tone, increase of capillary filtra-
tion pressure, loosening of interendothelial junc-
tions) which are induced by bradykinin, histamine, 
or arachidonic acid metabolites. The irreversible vas-
cular leakage in the later phases of the respiratory 
distress syndrome (ARDS), however, is due to struc-
tural injury of the vessels and alveoli, which may be 
primarily caused by lysosomal proteinases released 
from activated granulocytes and macrophages (de-
tailed description by Neuhof 1990 and Neuhof and 
Fritz 1992). Since especially proteolytically active 
PMN elastase in the presence of inactivated a{Pl 
was found in the bronchoalveolar lavage fluids of 
patients suffering from later stages of ARDS, we for 
the first time used suitable elastase inhibitors to pre-
vent otherwise irreversible vascular permeability due 
to elastase action in the rabbit lung model perfused 
with isolated human PMN granulocytes. 
As long as these cells were not additionally stim-
ulated in the lung circulation, they did not induce 
changes in vascular resistance or permeability dur-
ing a control period of 4 - 6 h. However, upon stim-
ulation with antigen-antibody complexes or heat-
denatured immunoglobulins, which were added to 
the perfusion fluid, pulmonary artery pressure and 
lung weight increased. The rise in pulmonary vas-
cular resistance was caused by thromboxane gener-
ated by the burst reaction of the granulocytes. 
Thus, the pressure increase could be blocked by a 
thromboxane receptor antagonist, whereas the ede-
ma formation continued. When PMN cells were 
stimulated in vitro and injected into the pulmonary 
circulation after finishing their burst reaction, there 
was no occurrence of either thromboxane genera-
tion or a pressure reaction. Yet edema formation 
still became obvious. 
Using prestimulated granulocytes or PMN cells 
stimulated within the pulmonary circulation, the de-
velopment of vascular leakage as reflected by an in-
crease in lung weight was paralleled by a rising level 
of P M N elastase in the perfusion fluid. Electron mi-
croscopy of such lungs showed vacuolated granulo-
cytes sticking to the endothelium of alveolar capil-
laries. The endothelial cells were injured and partial-
ly loosened from the vessel wall below the contact 
area. 
Similar results were obtained if purified PMN 
elastase was added to the perfusion fluid, reflecting 
the formation of interstitial edema. Again, pulmo-
nary artery pressure remained unchanged, indicat-
ing that the edema was a true permeability edema 
and not caused by hemodynamic changes in filtra-
tion pressure. 
The granulocyte-evoked edema formation could 
be largely suppressed by prophylactic infusion of the 
relatively specific recombinant elastase inhibitor 
eglin c (originally isolated from the leech Hirudo 
medicinalis as described by Seemüller et al. 1986), 
which is highly resistant to oxidative and proteolytic 
inactivation. Moreover, eglin c also prevented the in-
crease in fluid passage through monolayers of cul-
tured endothelial cells following their exposure to 
supernatants of activated granulocytes (Suttorp et 
al. 1989). 
In contrast to the protective effect of eglin c, ad-
dition of isolated humans a!PI to the perfusate up 
to a 40-fold molar surplus over the released elastase 
amount failed to inhibit the pulmonary permeability 
increase if PMN cells were stimulated in situ. This 
indicates at least a significant oxidative inactivation 
of the inhibitor by the released reactive oxygen spe-
cies. 
In view of the clinical need of an oxidant-resis-
tant PMN elastase inhibitor, we also tested a variant 
of the aprotinin molecule. Replacement of the lysine 
residue in the reactive center of the original plasmin/ 
trypsin inhibitor by valine using bioengineering 
techniques created a selective, nonoxidizable inhibi-
tor against PMN elastase (Wenzel et al. 1986). Simi-
lar to the effect of eglin c, the vascular leakage evok-
ed by in situ stimulation of granulocytes in the pul-
monary circulation was remarkably reduced by this 
inhibitor, thus further confirming the assumption 
that, out of all granulocytic proteinases, elastase 
contributes essentially to the irreversible edema for-
mation. 
Yet despite the fact that these elastase inhibitors 
have shown a high efficacy in our experimental lung 
model, their clinical application has to be consid-
ered with caution, especially concerning a putative 
antigenicity of these nonhuman proteins in long-
term studies. Thus, a therapeutic approach with an 
isolated, purified human ajPI preparation is still 
the only clinical choice at present. To overcome the 
inactivation mechanisms of this inhibitor in vivo, 
however, high amounts for substitution will be nec-
essary. 
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Conclusion 
The disturbance of pulmonary vascular permeabili-
ty due to multiple trauma and infection is caused 
by complex pathomechanisms in which a variety of 
mediators are involved. Of these, arachidonic acid 
metabolites, toxic oxygen species, and proteinases 
can be considered as important end products which 
directly affect the endothelial and epithelial barri-
ers. Since especially lysosomal proteinases from 
granulocytes and probably also from macrophages 
seem to be mainly responsible for the pulmonary 
vascular leakage that occurs in the later stages of 
ARDS and multiple organ failure, future concepts 
for prophylaxis and therapy should include not on-
ly blockers and antagonists of arachidonic acid me-
tabolites and antioxidants, but primarily proteinase 
inhibitors which are resistant to oxidative and pro-
teolytic inactivation. 
Concerning a putative antigenicity of nonhu-
man proteins, inhibitors of human origin seem to 
be preferable. Such inhibitors, however, can be easi-
ly inactivated by proteolysis and oxidation, in addi-
tion to the fact that the natural sources for the iso-
lation of proteinase inhibitors from human materi-
al are very limited. Thus, the design of highly effec-
tive inhibitory proteins on the basis of human in-
hibitor molecules by molecular modeling and their 
production by recombinant DNA technology is the 
most promising approach to obtain the quantities 
necessary for proteinase inhibition therapy in the 
future (Fritz et al. 1992). 
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